LDE Stock Overview Operates as an integrated contract development and manufacturing organization in the United States. More details
Rewards Risk Analysis + 1 more risk
See All Risk Checks Capture your thoughts, links and company narrative
Lifecore Biomedical, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Lifecore Biomedical Historical stock prices Current Share Price US$6.65 52 Week High US$7.80 52 Week Low US$3.38 Beta 1.0 1 Month Change 1.53% 3 Month Change 51.83% 1 Year Change 23.15% 3 Year Change -31.44% 5 Year Change n/a Change since IPO 33.00%
Recent News & Updates
Lifecore Biomedical, Inc. to Report Q2, 2025 Results on Jan 02, 2025 Dec 20
Investor sentiment improves as stock rises 17% Nov 12
Lifecore Biomedical, Inc. Appoints Jackie Klecker as Executive Vice President, Quality and Development Services Nov 05 Lifecore Biomedical, Inc. announced that it has received $24.307978 million in funding Oct 05
Lifecore Biomedical, Inc. Reiterates Financial Guidance for Full Year Fiscal 2025 Lifecore Biomedical Announces High-Speed, Multi-Purpose 5-Head Isolator Filler Is Gmp-Ready and Operational Sep 19
See more updates
Lifecore Biomedical, Inc. to Report Q2, 2025 Results on Jan 02, 2025 Dec 20
Investor sentiment improves as stock rises 17% Nov 12
Lifecore Biomedical, Inc. Appoints Jackie Klecker as Executive Vice President, Quality and Development Services Nov 05 Lifecore Biomedical, Inc. announced that it has received $24.307978 million in funding Oct 05
Lifecore Biomedical, Inc. Reiterates Financial Guidance for Full Year Fiscal 2025 Lifecore Biomedical Announces High-Speed, Multi-Purpose 5-Head Isolator Filler Is Gmp-Ready and Operational Sep 19
Lifecore Biomedical, Inc. Appoints Brikkelle Thompson as Senior Vice President of Human Resources Sep 11 Lifecore Biomedical Announces Chief Financial Officer Transition Aug 29
Lifecore Biomedical, Inc. Provides Earnings Guidance for Full Year Fiscal 2025 Aug 27 Lifecore Biomedical, Inc. announced delayed annual 10-K filing Aug 13
Third quarter 2024 earnings released: EPS: US$0.48 (vs US$0.51 loss in 3Q 2023) Aug 11 Gainey Mckenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Lifecore Biomedical, Inc Jul 31
Lifecore Biomedical, Inc. Announces Board Changes Jul 01
Lifecore Biomedical Receives Notification Letter from Nasdaq Regarding Non-Compliance with the Requirements for Continued Listing Under Nasdaq Listing Rule 5620(a) Jun 08
Lifecore Biomedical, Inc., Annual General Meeting, Aug 15, 2024 May 10 Lifecore Biomedical, Inc. announced delayed 10-Q filing Apr 09
Lifecore Biomedical, Inc. Provides Revenue Guidance for Full Year Fiscal 2024 Apr 03 Lifecore Biomedical, Inc. Announces Chief Executive Officer Changes, Effective May 20, 2024
Lifecore Biomedical Announces Receipt of Nasdaq Notice of Delisting and Intention to Appeal Feb 17
Lifecore Biomedical, Inc. Receives Notice from Nasdaq Regarding Delayed Quarterly Report Jan 13 Lifecore Biomedical, Inc. announced delayed 10-Q filing Jan 11
Lifecore Biomedical, Inc. Receives Notice from Nasdaq Regarding Delayed Annual Report Oct 19
Lifecore Biomedical, Inc. announced delayed 10-Q filing Oct 11
Lifecore Biomedical Receives Notice from Nasdaq Regarding Delayed Quarterly Report Aug 23
Lifecore Biomedical, Inc.(NasdaqGS:LFCR) dropped from Russell 2000 Dynamic Index Jun 25
Third quarter 2023 earnings released: US$0.51 loss per share (vs US$0.24 loss in 3Q 2022) Jun 02
High number of new directors Apr 09
Lifecore Biomedical Receives A Notification Letter from Nasdaq Due to Delay in Filing Its Quarterly Report on Form 10-Q for the Period Ended November 27, 2022 Jan 12 Lifecore Biomedical, Inc. announced that it has received $38.75 million in funding from Legion Partners Asset Management, LLC, 22NW, LP, 325 Capital, LLC, Cove Street Partners, Wynnefield Capital, Inc. Jan 11
Lifecore Biomedical, Inc. announced delayed 10-Q filing Lifecore Biomedical, Inc. announced that it has received $5.003136 million in funding Nov 27
Landec Corporation Reiterates Revenue Guidance for the Full Year Fiscal 2023 Oct 07
Landec Corporation to Report Q1, 2023 Results on Oct 06, 2022 Sep 29
Landec Corporation, Annual General Meeting, Nov 01, 2022 Sep 20
Landec Corp. Receives Notice from Nasdaq Regarding Delayed Annual Report Sep 12
Landec Corporation announced delayed annual 10-K filing Aug 16
Full year 2022 earnings released: US$1.56 loss per share (vs US$1.12 loss in FY 2021) Aug 12 Landec Corporation Provides Revenue Guidance for the Full Year Fiscal 2023
Landec Corporation(NasdaqGS:LNDC) dropped from Russell 2000 Value-Defensive Index Jun 26
High number of new directors Apr 27
Third quarter 2022 earnings released: US$0.24 loss per share (vs US$0.19 loss in 3Q 2021) Apr 07
Landec Corporation Reiterates Consolidated Earnings Guidance for the Fiscal Year 2022 Apr 06
High number of new directors Feb 02
Independent Director recently bought €91k worth of stock Jan 15
Second quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat Jan 06 Landec Corporation Provides Consolidated Revenue Guidance for Full Year Fiscal 2022
Landec Corporation Provides Earnings Guidance for the First Half, Second Half and Full Year of Fiscal 2022 Oct 02
First quarter 2022 earnings released: US$322 loss per share (vs US$0.38 loss in 1Q 2021) Sep 30
Full year 2021 earnings released: US$1.12 loss per share (vs US$1.31 loss in FY 2020) Jul 30
High number of new directors Jul 27
President of Lifecore recently bought €89k worth of stock Apr 16
Third quarter 2021 earnings released: US$0.19 loss per share (vs US$0.40 loss in 3Q 2020) Apr 09
Landec Corporation Provides Revenue Guidance for the Full Fiscal Year 2021 Apr 08 Shareholder Returns LDE DE Life Sciences DE Market 7D -7.0% -2.8% -2.6% 1Y 23.1% -5.9% 6.9%
See full shareholder returns
Return vs Market: LDE exceeded the German Market which returned 6.9% over the past year.
Price Volatility Is LDE's price volatile compared to industry and market? LDE volatility LDE Average Weekly Movement 9.5% Life Sciences Industry Average Movement 7.1% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.2% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: LDE's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: LDE's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States. The company engages in the manufacturing of injectable grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, such as technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products.
Show more Lifecore Biomedical, Inc. Fundamentals Summary How do Lifecore Biomedical's earnings and revenue compare to its market cap? LDE fundamental statistics Market cap €255.54m Earnings (TTM ) €5.47m Revenue (TTM ) €123.10m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) LDE income statement (TTM ) Revenue US$128.44m Cost of Revenue US$83.94m Gross Profit US$44.51m Other Expenses US$38.80m Earnings US$5.71m
Last Reported Earnings
Aug 25, 2024
Next Earnings Date
Jan 02, 2025
Earnings per share (EPS) 0.16 Gross Margin 34.65% Net Profit Margin 4.45% Debt/Equity Ratio 323.8%
How did LDE perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/22 19:56 End of Day Share Price 2024/12/20 00:00 Earnings 2024/08/25 Annual Earnings 2024/05/26
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Lifecore Biomedical, Inc. is covered by 12 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Alexander Paris Barrington Research Associates, Inc. Michael Petusky Barrington Research Associates, Inc. Matthew Hewitt Craig-Hallum Capital Group LLC
Show 9 more analysts 